Evidence map›Paper›PMID 34281377›Full record

ArticleStroke2021

Endovascular Treatment Effect Diminishes With Increasing Thrombus Perviousness: Pooled Data From 7 Trials on Acute Ischemic Stroke.

Manon Kappelhof, Manon L Tolhuisen, Kilian M Treurniet, Bruna G Dutra, Heitor Alves, Guang Zhang, Scott Brown, Keith W Muir, Antoni Dávalos, Yvo B W E M Roos and 15 more

Open access · hybridAbstract read
In one paragraph

Article in Stroke, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 13 institutions in 9 countries.

Manon KappelhofRadiology and Nuclear Medicine (M.K., M.L.T., K.M.T., B.G.D., H.A., G.Z., H.A.M., C.B.L.M.M.).ORCID 0000-0001-5250-8955
Manon L TolhuisenRadiology and Nuclear Medicine (M.K., M.L.T., K.M.T., B.G.D., H.A., G.Z., H.A.M., C.B.L.M.M.).ORCID 0000-0002-2695-1117
Kilian M TreurnietRadiology and Nuclear Medicine (M.K., M.L.T., K.M.T., B.G.D., H.A., G.Z., H.A.M., C.B.L.M.M.).
Bruna G DutraRadiology and Nuclear Medicine (M.K., M.L.T., K.M.T., B.G.D., H.A., G.Z., H.A.M., C.B.L.M.M.).ORCID 0000-0001-9753-1462
Heitor AlvesRadiology and Nuclear Medicine (M.K., M.L.T., K.M.T., B.G.D., H.A., G.Z., H.A.M., C.B.L.M.M.).
Guang ZhangRadiology and Nuclear Medicine (M.K., M.L.T., K.M.T., B.G.D., H.A., G.Z., H.A.M., C.B.L.M.M.).
Scott BrownAltair Biostatistics, St Louis Park, MN (S. Brown).
Keith W MuirNeuroscience & Psychology, University of Glasgow, Queen Elizabeth University Hospital, United Kingdom (K.W.M.).
Antoni DávalosNeuroscience, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Spain (A.D.).
Yvo B W E M RoosNeurology (Y.B.W.E.M.R.), Amsterdam University Medical Center, University of Amsterdam, the Netherlands.
Jeffrey L SaverNeurology, Comprehensive Stroke Center, David Geffen School of Medicine, University of California, Los Angeles (UCLA) (J.L.S.).
Andrew M DemchukClinical Neurosciences (A.M.D., M.D.H.), University of Calgary, Alberta, Canada.
Tudor G JovinNeurology, University of Pittsburgh Medical Center, PA (T.G.J.).
Serge BracardDiagnostic and Interventional Neuroradiology (S. Bracard), University of Lorraine, University Hospital of Nancy, France.
Bruce C V CampbellMedicine and Neurology (B.C.V.C.), Royal Melbourne Hospital, University of Melbourne, Parkville, Australia.
Aad van der LugtRadiology and Nuclear Medicine (A.v.d.L.), Erasmus Medical Center, Rotterdam, the Netherlands.
Francis GuilleminEpidemiology (F.G.), University of Lorraine, University Hospital of Nancy, France.
Philip WhiteInstitute of Neuroscience, Newcastle University, Newcastle upon Tyne, United Kingdom (P.W.).
Michael D HillClinical Neurosciences (A.M.D., M.D.H.), University of Calgary, Alberta, Canada.
Diederik W J DippelNeurology (D.W.J.D.), Erasmus Medical Center, Rotterdam, the Netherlands.
Peter J MitchellRadiology (P.J.M.), Royal Melbourne Hospital, University of Melbourne, Parkville, Australia.
Mayank GoyalRadiology (M.G.), University of Calgary, Alberta, Canada.
Henk A MarqueringRadiology and Nuclear Medicine (M.K., M.L.T., K.M.T., B.G.D., H.A., G.Z., H.A.M., C.B.L.M.M.).
Charles B L M MajoieRadiology and Nuclear Medicine (M.K., M.L.T., K.M.T., B.G.D., H.A., G.Z., H.A.M., C.B.L.M.M.).
HERMES Collaborators
Mahindra and Mahindra Limited (India) · INUniversity of Calgary · CAErasmus MC · NLThe Royal Melbourne Hospital · AUAltair Engineering (United States) · USAmsterdam University Medical Centers · NLCentre Hospitalier Régional et Universitaire de Nancy · FRHospital Universitari Germans Trias i Pujol · ESNewcastle University · GBQueen Elizabeth University Hospital · GBUniversité de Lorraine · FRUniversity of California, Los Angeles · USUniversity of Pittsburgh Medical Center · US

Funding

Medical Research Council MR/N003403/1
6 · The paper itself

Abstract

Background and Purpose: Thrombus perviousness estimates residual flow along a thrombus in acute ischemic stroke, based on radiological images, and may influence the benefit of endovascular treatment for acute ischemic stroke. We aimed to investigate potential endovascular treatment (EVT) effect modification by thrombus perviousness. Methods: We included 443 patients with thin-slice imaging available, out of 1766 patients from the pooled HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke trials) data set of 7 randomized trials on EVT in the early window (most within 8 hours). Control arm patients (n=233) received intravenous alteplase if eligible (212/233; 91%). Intervention arm patients (n=210) received additional EVT (prior alteplase in 178/210; 85%). Perviousness was quantified by thrombus attenuation increase on admission computed tomography angiography compared with noncontrast computed tomography. Multivariable regression analyses were performed including multiplicative interaction terms between thrombus attenuation increase and treatment allocation. In case of significant interaction, subgroup analyses by treatment arm were performed. Our primary outcome was 90-day functional outcome (modified Rankin Scale score), resulting in an adjusted common odds ratio for a one-step shift towards improved outcome. Secondary outcomes were mortality, successful reperfusion (extended Thrombolysis in Cerebral Infarction score, 2B–3), and follow-up infarct volume (in mL). Results: Increased perviousness was associated with improved functional outcome. After adding a multiplicative term of thrombus attenuation increase and treatment allocation, model fit improved significantly (P=0.03), indicating interaction between perviousness and EVT benefit. Control arm patients showed significantly better outcomes with increased perviousness (adjusted common odds ratio, 1.2 [95% CI, 1.1–1.3]). In the EVT arm, no significant association was found (adjusted common odds ratio, 1.0 [95% CI, 0.9–1.1]), and perviousness was not significantly associated with successful reperfusion. Follow-up infarct volume (12% [95% CI, 7.0–17] per 5 Hounsfield units) and chance of mortality (adjusted odds ratio, 0.83 [95% CI, 0.70–0.97]) decreased with higher thrombus attenuation increase in the overall population, without significant treatment interaction. Conclusions: Our study suggests that the benefit of best medical care including alteplase, compared with additional EVT, increases in patients with more pervious thrombi.

Indexed as

Ischemic StrokeRecovery of FunctionThrombosisAgedClinical Trials as TopicComputed Tomography AngiographyEndovascular ProceduresFemaleFibrinolytic AgentsHumansMaleMiddle AgedRandomized Controlled Trials as TopicThrombectomyTissue Plasminogen ActivatorTomography, X-Ray ComputedFibrinolytic AgentsTissue Plasminogen Activatorcerebral infarctiondecision makingreperfusionstrokethrombectomytissue-type plasminogen activator

Identifiers

PMID34281377
PMCPMC8547583
OpenAlexW3185502019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.